cenisertib
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00391521)
Timeline
2000s
- Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
AURKA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1- Mol. weight
- 451.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL1967878 ↗
Also known as
- as703569
- as703569
- as703569
- as-703569
- as-703569
- cenisertib
- cenisertib
- msc1992371a
- r763 compound
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01097512 | Phase 1 | Jun 1, 2007 | Merck KGaA, Merck Serono |
| NCT01080664 | Phase 1 | Dec 1, 2006 | Merck Serono |
| NCT00391521 | Phase 1 | Aug 1, 2006 | Merck Serono |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck Serono | For profit | 3 | 2 | 1 | 2006 |
| Merck KGaA | For profit | 1 | 1 | 1 | 2007 |
2 organizations
Page 1 / 1